USP site in China
This article was originally published in The Tan Sheet
Executive Summary
U.S. Pharmacopeia's newest international site in Shanghai will enable the organization to work with Chinese regulators and manufacturers to ensure the safety of dietary supplements, pharmaceuticals and food ingredients, USP states in a Sept. 6 release. The opening of the site was celebrated with a ribbon-cutting ceremony Sept. 8, which was attended by USP executives as well as State Food and Drug Administration officials, among others. "USP-China will work closely with SFDA, the Chinese Pharmacopeia Commission, [the National Institute for the control of Pharmaceutical and Biological Products] and other constituencies to help ensure the quality of medicines and food ingredients," USP says. "Our presence will benefit Chinese manufacturers, government agencies and ultimately patients in China, U.S. and the many countries to which China exports," organization adds. SFDA recently announced it was planning to spend 8.8 bil. yuan ($1.1 bil.) over the next three to five years to strengthen food and drug oversight and infrastructure (1"The Tan Sheet" Aug. 27, 2007, In Brief)...
You may also be interested in...
China food safety efforts
China will spend 8.8 bil. yuan ($1.1 bil.) during the next three to five years to strengthen food and drug oversight and infrastructure, China's State Food and Drug Administration Spokeswoman Yan Jiangying said during a press conference in Beijing Aug. 8. Approximately 6.3 bil. yuan ($790 mil.) will be funded by the central government for initiatives in Western and Central China, while the rest will come from local governments in Eastern China, she added. On May 24, SFDA announced the "2007 National Plan of Special Rectification of Food Safety" to improve the safety of food eaten in China and exported food (1"The Tan Sheet" June 4, 2007, p. 12). In other safety news, Yan noted SFDA has released a list of Web sites that may legally sell drugs online, including four retail sites authorized to sell nonprescription drugs to consumers...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.